CN102340993A - 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物 - Google Patents

向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物 Download PDF

Info

Publication number
CN102340993A
CN102340993A CN2010800101411A CN201080010141A CN102340993A CN 102340993 A CN102340993 A CN 102340993A CN 2010800101411 A CN2010800101411 A CN 2010800101411A CN 201080010141 A CN201080010141 A CN 201080010141A CN 102340993 A CN102340993 A CN 102340993A
Authority
CN
China
Prior art keywords
suspension
peg
composition
active agent
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800101411A
Other languages
English (en)
Chinese (zh)
Inventor
B·P·卡布拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Research LLC
Original Assignee
Alcon Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Research LLC filed Critical Alcon Research LLC
Priority to CN201510767618.5A priority Critical patent/CN105362221A/zh
Publication of CN102340993A publication Critical patent/CN102340993A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800101411A 2009-03-03 2010-03-03 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物 Pending CN102340993A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510767618.5A CN105362221A (zh) 2009-03-03 2010-03-03 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15698409P 2009-03-03 2009-03-03
US61/156,984 2009-03-03
PCT/US2010/025998 WO2010101971A1 (en) 2009-03-03 2010-03-03 Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510767618.5A Division CN105362221A (zh) 2009-03-03 2010-03-03 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物

Publications (1)

Publication Number Publication Date
CN102340993A true CN102340993A (zh) 2012-02-01

Family

ID=42678477

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800101411A Pending CN102340993A (zh) 2009-03-03 2010-03-03 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物
CN201510767618.5A Pending CN105362221A (zh) 2009-03-03 2010-03-03 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510767618.5A Pending CN105362221A (zh) 2009-03-03 2010-03-03 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物

Country Status (11)

Country Link
US (1) US20100226992A1 (enExample)
EP (1) EP2403342A4 (enExample)
JP (1) JP5583145B2 (enExample)
KR (1) KR20110123789A (enExample)
CN (2) CN102340993A (enExample)
AU (1) AU2010221438C1 (enExample)
BR (1) BRPI1008920A2 (enExample)
CA (1) CA2753837A1 (enExample)
MX (1) MX2011008680A (enExample)
WO (1) WO2010101971A1 (enExample)
ZA (1) ZA201105506B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107708664A (zh) * 2015-06-22 2018-02-16 新源生物科技股份有限公司 酪胺酸激酶抑制剂的眼用调配物、其使用方法、及其制备方法
WO2023103835A1 (zh) * 2021-12-09 2023-06-15 成都瑞沐生物医药科技有限公司 一种酪氨酸激酶抑制剂眼用制剂及其制备方法和用途

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3252079B8 (en) 2006-04-07 2020-09-09 Aerpio Therapeutics LLC Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
TW201023912A (en) 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
WO2010101989A1 (en) 2009-03-03 2010-09-10 Alcon Research, Ltd. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
PL2451279T3 (pl) 2009-07-06 2019-09-30 Aerpio Therapeutics, Inc. Pochodne benzosulfonamidowe, ich kompozycje i ich zastosowanie w zapobieganiu przerzutom komórek nowotworowych
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint Pharmaceuticals, Inc. Methods for treating Vascular Leak Syndrome and cancer
TW201330850A (zh) * 2011-12-14 2013-08-01 Abbvie Inc 包含激酶抑制劑之組合物
EP2825166A1 (en) * 2012-03-12 2015-01-21 Allergan, Inc. Method of treating ophthalmic conditions with kinase inhibitors
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
TW201518291A (zh) 2013-09-20 2015-05-16 參天製藥股份有限公司 含聚乙二醇之組成物
US9994560B2 (en) 2014-03-14 2018-06-12 Aerpio Therapeutics, Inc. HPTP-β inhibitors
MA56220A (fr) * 2014-09-17 2022-04-20 Panoptica Inc Formulations oculaires permettant l'administration de médicament et la protection du segment antérieur de l'oeil
EP3302061A4 (en) * 2015-06-05 2019-02-27 Kato Pharmaceuticals, Inc. UREA COMPOSITIONS WITH EXTENDED RELEASE
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
WO2020223209A1 (en) 2019-04-29 2020-11-05 Aerpio Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
WO2021051003A1 (en) * 2019-09-13 2021-03-18 Aldeyra Therapeutics, Inc. Ophthalmic formulations of methotrexate
US12337012B2 (en) 2019-09-27 2025-06-24 Virginia Commonwealth University Compositions and methods for restoring or increasing tissue perfusion

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030165486A1 (en) * 1999-12-03 2003-09-04 Karageozian Hampar L. Compositions and methods for the induction of retinal detachments
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US20070149480A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070249546A1 (en) * 2006-04-22 2007-10-25 Sawaya Assad S Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
CN101163465A (zh) * 2005-02-23 2008-04-16 爱尔康公司 使用选择性rtk抑制剂治疗眼部血管发生、视网膜水肿、视网膜缺血和糖尿病视网膜病变的方法
WO2009014510A1 (en) * 2007-07-20 2009-01-29 Alcon, Inc. Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856919A (en) * 1970-06-08 1974-12-24 Burton Parsons Chemicals Inc Ophthalmic solution
US3931319A (en) * 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
US4027020A (en) * 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4525346A (en) * 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4836986A (en) * 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5037647A (en) * 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5932572A (en) * 1992-02-21 1999-08-03 Alcon Laboratories, Inc. Topical anti-glaucoma compositions
US5300287A (en) * 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
CA2153234C (en) * 1993-04-16 1999-02-16 Masanobu Takeuchi Aqueous drug composition having property of reversible thermosetting gelation
EP0842663A4 (en) * 1996-05-07 2003-06-18 Toray Industries OPHTHALMIC PREPARATIONS
PT970175E (pt) * 1997-07-29 2003-02-28 Alcon Lab Inc Solucoes de acondicionamento para cuidar de lentes de contacto rigidas
AU6870800A (en) * 1999-09-06 2001-04-10 Ono Pharmaceutical Co. Ltd. Preventive and therapeutic agents for eye diseases
PL201130B1 (pl) * 1999-09-24 2009-03-31 Alcon Inc Kompozycje zawiesinowe zawierające ciprofloksacynę i deksametazon do podawania miejscowego do oczu, uszu lub nosa
WO2001087262A2 (en) * 2000-05-15 2001-11-22 Pharmacia Italia S.P.A. Stabilized steroidal suspension
US20020037877A1 (en) * 2000-07-26 2002-03-28 Alcon Universal Ltd. Pharmaceutical suspension compositions lacking a polymeric suspending agent
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
DK1429780T3 (da) * 2001-09-21 2006-02-13 Fremgangsmåde til behandling af mellemoreinfektioner
US7001615B1 (en) * 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
MXPA05000232A (es) * 2002-06-21 2005-06-17 Transform Pharmaceuticals Inc Composiciones farmaceuticas con disolucion mejorada.
US20040235892A1 (en) * 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
JP4810427B2 (ja) * 2003-05-22 2011-11-09 アボット・ラボラトリーズ インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤
CA2562356A1 (en) * 2004-04-08 2005-10-27 Retmed Pty Ltd Treatment of ophthalmic conditions with mineralcorticoids
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
WO2006121964A2 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
PT1885336E (pt) * 2005-05-10 2009-05-07 Alcon Inc Formulações de suspensão compreendendo um princípio activo, um tensoactivo poloxâmero ou meroxapol e um glicol, sua utilização no fabrico de um medicamento para tratamento de distúrbios oftálmicos
US20070149593A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
TW201023912A (en) * 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030165486A1 (en) * 1999-12-03 2003-09-04 Karageozian Hampar L. Compositions and methods for the induction of retinal detachments
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
CN101163465A (zh) * 2005-02-23 2008-04-16 爱尔康公司 使用选择性rtk抑制剂治疗眼部血管发生、视网膜水肿、视网膜缺血和糖尿病视网膜病变的方法
US20070149480A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070249546A1 (en) * 2006-04-22 2007-10-25 Sawaya Assad S Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
WO2009014510A1 (en) * 2007-07-20 2009-01-29 Alcon, Inc. Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107708664A (zh) * 2015-06-22 2018-02-16 新源生物科技股份有限公司 酪胺酸激酶抑制剂的眼用调配物、其使用方法、及其制备方法
CN107708664B (zh) * 2015-06-22 2021-10-19 新源生物科技股份有限公司 酪胺酸激酶抑制剂的眼用调配物、其使用方法、及其制备方法
WO2023103835A1 (zh) * 2021-12-09 2023-06-15 成都瑞沐生物医药科技有限公司 一种酪氨酸激酶抑制剂眼用制剂及其制备方法和用途

Also Published As

Publication number Publication date
US20100226992A1 (en) 2010-09-09
AU2010221438C1 (en) 2015-01-29
ZA201105506B (en) 2012-09-26
MX2011008680A (es) 2011-09-08
BRPI1008920A2 (pt) 2015-08-25
CA2753837A1 (en) 2010-09-10
JP2012519692A (ja) 2012-08-30
EP2403342A1 (en) 2012-01-11
JP5583145B2 (ja) 2014-09-03
EP2403342A4 (en) 2013-06-05
CN105362221A (zh) 2016-03-02
AU2010221438B2 (en) 2014-10-16
AU2010221438A1 (en) 2011-08-25
KR20110123789A (ko) 2011-11-15
WO2010101971A1 (en) 2010-09-10

Similar Documents

Publication Publication Date Title
CN102340991B (zh) 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物
CN102340993A (zh) 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物
US20070149593A1 (en) PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US10765677B2 (en) Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
EP2142189B1 (en) Methods and compositions for intraocular administration to treat ocular conditions
US20070149480A1 (en) PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CN101687042A (zh) 用于递送作为受体酪氨酸激酶抑制剂(RTKi)的化合物至眼部的药物制剂
US20070173538A1 (en) PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
Jain et al. A Review on Triggered Gel for Ocular Drug Delivery

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120201